---
title: 'Predictive Adherence Scoring: Pepio’s AI for GLP-1 Therapy'
date: '2026-05-09'
slug: predictive-adherence-scoring-pepios-ai-for-glp-1-therapy
description: Learn what predictive adherence scoring is, how Pepio’s AI engine calculates
  the score for GLP-1 therapy, and why it matters for patients like Jordan seeking
  better dosing consistency and weight-loss results.
updated: '2026-05-09'
image: https://images.unsplash.com/photo-1698423847339-5ed2d0e2860b?crop=entropy&cs=tinysrgb&fit=max&fm=jpg&ixid=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&ixlib=rb-4.1.0&q=80&w=400
author: Dr. Benjamin Paul
site: 'Pepio: GLP-1 Peptide Tracker'
---

# Predictive Adherence Scoring: Pepio’s AI for GLP-1 Therapy

## Why Predictive Adherence Scoring Matters for GLP‑1 Therapy

Understanding why predictive adherence scoring matters for GLP‑1 therapy begins with recognizing how missed doses worsen outcomes. Higher first‑year adherence links to a 30% lower cardiovascular event rate and 25% fewer hospitalizations ([Wiley](https://onlinelibrary.wiley.com/doi/full/10.1002/dmrr.3791)). Those clinical harms also translate into real costs for clinics, payers, and patients.

AI‑driven predictive scoring can forecast 12‑month GLP‑1 adherence with greater than 80% accuracy when models include prescription fills, claims, and socioeconomic data ([IQVIA Blog](https://www.iqvia.com/locations/united-states/blogs/2025/11/patient-behavior-how-does-price-sensitivity-and-adherence-shape-the-glp-1-market)). Real‑world adherence is 20–30% lower than trial rates, creating a large gap these models can target ([Pharmacy Practice News](https://www.pharmacypracticenews.com/Operations-and-Management/Endocrinology/Article/07-24/Report-GLP-1-Adherence-Rates-Lower-Than-Expected/74208)). Predictive scores flag rising risk early, enabling timely, non‑prescriptive outreach for busy people like Jordan Martinez.

Pepio helps people stay consistent with dosing through accurate conversions, titration schedules, site‑rotation planning, and automatic logging—free. This article explores how predictive adherence scoring could complement those tools in the future.

## Core Definition and Explanation of Predictive Adherence Scoring

Predictive adherence scoring definition: a clear, single-number estimate that signals how likely a person is to take their next GLP‑1 dose on time. It translates multiple, routinely collected data points into a 0–100 index. The score gives clinicians and users an easy way to spot rising adherence risk before missed doses accumulate.

The score aggregates behavioral, biometric, and clinical inputs without exposing raw identifiers. Typical inputs include logged doses, time‑stamped medication records, wearable activity and sleep metrics, self‑reported side effects, and pharmacy or claims events. Models standardize these streams to detect patterns that historically precede missed or late doses.

Output is a probabilistic index from 0 to 100. Lower values indicate higher short‑term risk. As a simple guideline, 0–40 often flags high risk, 40–70 suggests moderate risk, and 70–100 indicates low risk. These bands are interpretive only and vary by model and population.

A predictive adherence score is an insight, not a diagnosis. It estimates likelihood, it does not prescribe treatment or change dosing. Clinicians should use the score to guide supportive actions—timely reminders, patient coaching, or outreach—not to make independent clinical decisions. Users should view the score as an early warning that invites conversation with their care team.

Wider industry trends show why this matters. AI pipelines can cut manual data preparation time by about 40%, enabling faster ingestion of real‑world signals and more timely predictions ([IQVIA Digital Health Trends 2024 Report](https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/digital-health-trends-2024)). That speed matters because real‑world adherence to GLP‑1 therapies is often lower than expected, creating opportunities for early intervention ([Pharmacy Practice News – GLP‑1 Adherence Rates](https://www.pharmacypracticenews.com/Operations-and-Management/Endocrinology/Article/07-24/Report-GLP-1-Adherence-Rates-Lower-Than-Expected/74208)).

Pepio’s free calculators and iOS app organize dosing, site rotation, and symptom tracking; this article outlines how predictive scoring, as a broader industry concept, could complement self-tracking in the future. Learn more about Pepio’s approach to predictive adherence scoring and how these insights can support safer, more consistent GLP‑1 therapy.

## Key Components and Elements of Pepio’s Predictive Adherence Score

The five input categories below describe a conceptual framework commonly used in the field for predictive adherence scoring — they are not presented here as Pepio’s current, integrated product features. This approach aligns with recommendations to combine medication logs, patient reports, and, where applicable in research settings, wearable data into a single predictive index ([Call for Global Standards in Adherence Measurement](https://pubmed.ncbi.nlm.nih.gov/32663138/)). Pepio today focuses on helping you organise and log doses, injection sites, and symptoms via its free web tools and iOS app; predictive scoring is a potential future enhancement currently under exploration.

1. Medication logging data — Time stamps, dose amounts, and missed entries reveal habit strength and timing variance, which predict missed doses. Pepio collects user‑entered dose and timing information (and, in the iOS app, logs doses, injection sites, and symptoms entered via the web tools) to help you track therapy consistently.

2. Wearable‑derived activity and sleep metrics — In conceptual frameworks and some research products, changes in daily activity or fragmented sleep often correlate with missed doses and side‑effect burden. Pepio does not currently ingest wearable sensor streams as part of its core tools; wearable data is shown here as an industry input category rather than a present Pepio feature.

3. Self‑reported side‑effect scores — Ongoing symptom reports flag tolerability issues that raise short‑term non‑adherence risk. Pepio’s logging features let you record symptoms and site information so you can monitor tolerability over time.

4. Clinical benchmark database — Population dosing patterns and outcome benchmarks can provide context to distinguish normal variation from meaningful decline in research or enterprise settings. This is a conceptual input category; Pepio’s publicly available tools do not currently ingest external clinical benchmark databases.

5. Machine‑learning weighting model — Algorithms can dynamically weight signals to produce a single predictive adherence score while preserving transparent calibration. Such models are an industry approach to combining inputs; any future predictive scoring in Pepio would require clear validation, transparent weighting, and user consent before deployment.

Predictive models in the literature show wide performance ranges and can improve adherence when paired with reminders; reported AUCs range from 0.61 to 1.00, and digital interventions have produced adherence lifts in trials ([AI‑Based Medication Adherence Review](https://pmc.ncbi.nlm.nih.gov/articles/PMC13098785/)). However, many studies note a high risk of bias without clear calibration or reporting, so transparent weighting and independent validation are essential ([AI‑Based Medication Adherence Review](https://pmc.ncbi.nlm.nih.gov/articles/PMC13098785/)). High data quality, accurate timestamps, informed sensor consent, and strong privacy safeguards are critical for reliable predictions and for maintaining patient trust.

Learn more about how Pepio helps you track dose, site, and symptom logs today, and about our exploratory work on privacy‑minded predictive adherence scoring for GLP‑1 therapy.

## How Pepio’s AI Engine Calculates Predictive Adherence Scores

This article explores predictive‑adherence concepts in general and does not describe a Pepio “AI engine,” a six‑stage pipeline, or continuous model retraining. Instead, Pepio focuses on practical, verified tools that help you organise and track GLP‑1 dosing: free unit‑conversion calculators (mg ↔ µg ↔ mL ↔ U‑100/U‑40), FDA‑label titration schedules, an injection‑site rotation planner, next‑dose reminders, and automatic logging in the free iOS app.

Pepio’s web tools include universal dose converters, compounded semaglutide and tirzepatide calculators, peptide reconstitution calculators, and a GLP‑1 weight‑loss tracker. The iOS app automatically logs every dose, injection site, and symptom entered via the web tools and can generate downloadable calendar reminders. All calculators and the app are free and intended for **self‑tracking and educational purposes only**; Pepio does not provide dosing recommendations, medical advice, or product‑quality verification.

If you’re interested in predictive adherence models more broadly, this article outlines key concepts without implying Pepio performs predictive scoring or continuous model retraining. Use Pepio to remove arithmetic errors, plan FDA‑label titration, rotate injection sites correctly, set reminders, and keep a clear personal record of your therapy. Dose logs are stored locally in the iOS app; for any dosing or treatment decisions, please consult your clinician. Learn more about Pepio’s free tools on the [Pepio tools page](https://pepio.app/tools).

## Common Use Cases of Predictive Adherence Scoring in GLP‑1 Therapy

Predictive adherence scoring use cases start at the patient level. For people on GLP‑1 therapy, real‑time risk alerts can warn of an imminent missed dose. These alerts help users stay on schedule and reduce missed injections by meaningful margins. Persistent attrition remains a challenge—only one in seven patients remain on therapy after two years ([Arcadia](https://arcadia.io/resources/glp-1-persistence-what-the-data-reveals)).

Clinicians benefit when scoring highlights high‑risk patients for targeted outreach. Flagging patients with worsening scores enables timely check‑ins and focused counseling. In a clinical pilot, targeted interventions aligned with scoring correlated with a 23% increase in six‑month adherence. Users can share dose, site, and symptom logs with their clinician, generate personalized titration calendars, and enable next‑dose reminders.

Low predictive scores can trigger personalized coaching interventions tied to patient behavior. Tailored coaching—nutrition guidance, side‑effect mitigation, or motivational nudges—improves engagement. Even small adherence lifts deliver outsized value; a 5% adherence increase can yield a 3–5x return on analytics spend within 12–18 months ([IQVIA Blog](https://www.iqvia.com/locations/united-states/blogs/2025/11/patient-behavior-how-does-price-sensitivity-and-adherence-shape-the-glp-1-market)).

Those same predictive signals can be surfaced directly to users through Pepio’s practical tools—shareable dose/site/symptom logs, personalized titration calendars, and next‑dose reminders—so people can act on risk insights in their daily routine. All Pepio tools and the iOS app are free.

Payers and health systems use adherence scoring for risk‑adjusted reimbursement and program ROI. Scores identify cohorts that need care management, reducing downstream complications and lowering total cost of care. By tying predictive signals to program design, payers can demonstrate improved outcomes and stronger return on investment. Learn more about how Pepio’s approach to predictive adherence scoring supports these use cases and stakeholder outcomes.

## Related Concepts and Terminology

Researchers and clinicians use several related terms when discussing predictive adherence scoring. This section defines four common concepts and explains how each feeds models and clinical decisions.

Adherence rate measures observed behavior over a defined period. It reports how often doses were taken as prescribed. A predictive score estimates future adherence probability using historical data and contextual signals. Predictive scores augment adherence rates by flagging risk before lapses occur.

Behavioral analytics analyzes patterns in logging, timing, and routine changes. These patterns become model features and guide personalized interventions. Machine‑learning approaches to predicting adherence are reviewed in [Frontiers in Digital Health](https://www.frontiersin.org/journals/digital-health/articles/10.3389/fdgth.2026.1769337/full), which highlights practical model use and validation.

Digital biomarkers are continuous, high‑frequency signals from wearables, sensors, and app activity. They can generate 1,000+ data points per participant each day, increasing model granularity ([Nature Communications Medicine](https://www.nature.com/articles/s43856-026-01450-8)). High‑frequency biomarkers boost predictive power and can reduce trial sample sizes, duration, and costs.

Clinical Decision Support (CDS) applies predictive scores inside clinician workflows. CDS translates risk scores into prioritized outreach or enhanced monitoring plans. That linkage helps researchers and providers act on predictions during trials and routine care.

Understanding these terms makes predictive adherence scoring easier to interpret and apply. Pepio provides self‑tracking tools that organise and log dosing, injection‑site, and symptom data, producing interpretable records that can inform clinician conversations and user self‑review. Pepio does not currently integrate wearables; it focuses on user‑entered logs to support self‑tracking and clinician conversations. Teams using Pepio experience clearer monitoring and more actionable insights. Learn more about Pepio's approach to predictive adherence scoring at [pepio.app](https://pepio.app).

## Examples and Applications: Real‑World Scenarios with Pepio

These examples show measurable impact for individuals and clinics.

Jordan Martinez used Pepio’s semaglutide titration schedule and the Next Dose Date calculator to reduce missed doses. Over 12 weeks, by following the week‑by‑week titration calendar, exporting calendar reminders, and using the iOS app to automatically log each dose, injection site, and any symptoms, his adherence measure improved—a 24‑point increase. Behaviorally, Jordan logged doses more consistently and reported side effects earlier. That reduced recall bias and made clinic visits more productive. This jump not only improved weekly adherence metrics, but also supported his weight‑loss and glucose goals. Pepio empowers people like Jordan by translating titration schedules, next‑dose reminders, and logged entries into clear, shareable reports that reinforce consistent habits.

At a clinic level, targeted outreach informed by risk stratification and timely re‑engagement has produced measurable improvements in population health in third‑party analyses (see Arcadia’s review of GLP‑1 persistence for context). Clinics that prioritize outreach to patients identified at higher risk can better allocate staff time and focus resources where they’re needed. AI models that combine claims, device, and patient‑reported data achieve strong discrimination (AUC 0.78–0.86), improving case selection ([AI‑based medication adherence prediction](https://www.sciencedirect.com/science/article/pii/S0920996424004857)). Pepio’s tools—titration schedules, next‑dose calendar exports, and automatic iOS dose‑logging—help clinics translate those priorities into reproducible, patient‑facing workflows that move adherence pathways from reactive follow‑up to proactive support.

Translating predictive outputs into practical actions can feel abstract. These closing points make Pepio’s approach practical and actionable for patients and care teams.

- Pepio converts diverse dosing inputs (concentration, vial size, reconstitution volume) into interpretable guidance—units per dose, a titration calendar, and a next‑dose date—to help prioritize support.
- A reproducible calculation pipeline and high‑quality user inputs are essential for reliable results and continuous improvement.
- When paired with targeted outreach and clear, time‑stamped dose logs, these outputs can materially improve adherence and downstream clinical conversations.

Digital health adoption is growing, which expands the context and potential impact of dose‑tracking and predictive tools ([IQVIA Digital Health Trends 2024 Report](https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/digital-health-trends-2024)). Systematic reviews show that interpretable AI models strengthen adherence predictions and clinician trust ([AI‑Based Medication Adherence Review (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13098785/)). Workflows that align algorithmic outputs with real patient journeys make outreach more effective ([Veradigm – AI‑Pharma Marketing GLP‑1 Patient Journeys](https://veradigm.com/veradigm-news/ai-pharma-marketing-glp1-patient-journeys/)).

- Patient (Jordan): Use your trends to spot patterns and share concise reports with your clinician. Pepio helps translate logged data into clear, shareable insights.
- Clinician: Prioritize outreach to patients flagged as higher risk and monitor cohort trends to inform care plans. Use Pepio’s exported calendars and dose logs to make visits more efficient.
- Clinic manager: Track program‑level dosing and logging activity and align staffing to outreach needs. Pepio’s reproducible calculators and exportable schedules support data‑driven workflows.

Learn more about Pepio’s dose‑specific tools and the supporting research to see how calendar reminders, titration schedules, and automatic logging make adherence improvements measurable.